

## Disclosure in accordance with the Law of 2 May 2007

Fagron NV discloses the information required under article 15, § 1 of the Law of 2 May 2007 regarding the disclosure of important shareholdings in listed companies.

Information as at 28 July 2016:

- Total share capital: € 494,192,221.68
- Total number of outstanding ordinary shares: 71,843,904
- Total number of outstanding warrants (each warrant entitles the holder to subscribe to one new ordinary share): 1,645,718
- Total number of outstanding options (each option entitles the holder to purchase from Fagron NV one existing ordinary share): 199,650

Article 11 of the articles of association of the company specifies that participations must be notified as soon as a threshold of 3%, 5% and any multiple of 5% has been passed.

Notifications of important shareholdings to be made according to the Law of 2 May 2007 and the articles of association of Fagron NV, should be sent to [constantijn.van.rietschoten@fagron.com](mailto:constantijn.van.rietschoten@fagron.com).

This information will be published on <http://investors.fagron.com>.

*In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.*

### For more information:

Constantijn van Rietschoten  
Chief Marketing Officer  
Tel. +31 6 53 69 15 85  
[constantijn.van.rietschoten@fagron.com](mailto:constantijn.van.rietschoten@fagron.com)

### Fagron profile

Fagron is the leading global pharmaceutical compounding company, bringing customized pharmaceutical care to hospitals, pharmacies, clinics and patients in 32 countries worldwide.

The Belgian company Fagron NV is located in Waregem and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol 'FAGR'. The operational activities of Fagron are driven by the Dutch company Fagron BV. The head office of Fagron BV is located in Rotterdam.

<sup>1</sup> This press release was sent out by Fagron NV and Fagron BV.

